Cerevel Therapeutics Statistics Share Statistics Cerevel Therapeutics has 182.2M
shares outstanding. The number of shares has increased by 0%
in one year.
Shares Outstanding 182.2M Shares Change (YoY) 0% Shares Change (QoQ) 0% Owned by Institutions (%) 94.04% Shares Floating 77.82M Failed to Deliver (FTD) Shares 4,782,602 FTD / Avg. Volume 232.56%
Short Selling Information The latest short interest is 10.28M, so 0% of the outstanding
shares have been sold short.
Short Interest 10.28M Short % of Shares Out n/a Short % of Float n/a Short Ratio (days to cover) 2.96
Valuation Ratios The PE ratio is -15.87 and the forward
PE ratio is -15.24.
Cerevel Therapeutics's PEG ratio is
-1.05.
PE Ratio -15.87 Forward PE -15.24 PS Ratio 0 Forward PS 130 PB Ratio 10.2 P/FCF Ratio -19.85 PEG Ratio -1.05
Financial Ratio History Enterprise Valuation Currently the Enterprise Value (EV) is not available for Cerevel Therapeutics.
EV / Sales n/a EV / EBITDA n/a EV / EBIT n/a EV / FCF n/a
Financial Position The company has a current ratio of 10.92,
with a Debt / Equity ratio of 0.71.
Current Ratio 10.92 Quick Ratio 10.92 Debt / Equity 0.71 Debt / EBITDA -1.09 Debt / FCF -1.39 Interest Coverage -42.33
Financial Efficiency Return on Equity is n/a and Return on Invested Capital is n/a.
Return on Equity n/a Return on Assets n/a Return on Invested Capital n/a Revenue Per Employee n/a Profits Per Employee $-1.22M Employee Count 355 Asset Turnover 0 Inventory Turnover n/a
Taxes Income Tax 503K Effective Tax Rate -0.12%
Stock Price Statistics The stock price has increased by 0% in the
last 52 weeks. The beta is 1.41, so Cerevel Therapeutics's
price volatility has been higher than the market average.
Beta 1.41 52-Week Price Change n/a 50-Day Moving Average 41.66 200-Day Moving Average 38.78 Relative Strength Index (RSI) 72.45 Average Volume (20 Days) 2,056,487
Income Statement
Revenue n/a Gross Profit -5.63M Operating Income -447.26M Net Income -432.84M EBITDA -441.64M EBIT -421.77M Earnings Per Share (EPS) -2.67
Full Income Statement Balance Sheet The company has 990.97M in cash and 480.78M in
debt, giving a net cash position of 510.19M.
Cash & Cash Equivalents 990.97M Total Debt 480.78M Net Cash 510.19M Retained Earnings -1.4B Total Assets 1.13B Working Capital 775.47M
Full Balance Sheet Cash Flow In the last 12 months, operating cash flow was -342.3M
and capital expenditures -3.81M, giving a free cash flow of -346.11M.
Operating Cash Flow -342.3M Capital Expenditures -3.81M Free Cash Flow -346.11M FCF Per Share -2.14
Full Cash Flow Statement Margins
Gross Margin n/a Operating Margin n/a Pretax Margin n/a Profit Margin n/a EBITDA Margin n/a EBIT Margin n/a FCF Margin n/a
